论文部分内容阅读
目的研究肝硬化患者前列地尔脂微球载体制剂(LiPoPGE1)治疗后血清ALT、AST变化的临床意义。方法采用全自动生化测定70例肝硬化患者和30例正常人血浆ALT、AS的含量。肝硬化患者随机分成两组,对照组30例,为综合治疗组;实验组40例为综合治疗加前列腺素E1(PCE1)。两组治疗前以上观察指标差异无显著性(P>0.05)。按Child分级,治疗前肝硬化患者血清ALT、AST水平两组均为A级0.05)。结论前列地尔脂微球载体制剂(LiPoPGE1)治疗肝硬化A、B两级患者具有降低ALT.AST的作用,从而推论前列地尔脂微球载体制剂(LiPoPGE1)具有保护肝细胞的作用。
Objective To study the clinical significance of serum ALT and AST after treatment with LiPoPGE1 in patients with liver cirrhosis. Methods Plasma levels of ALT and AS in 70 patients with cirrhosis and 30 normal controls were measured by automatic biochemical method. Patients with cirrhosis were randomly divided into two groups, the control group of 30 cases, for the comprehensive treatment group; 40 cases of experimental group for the comprehensive treatment plus prostaglandin E1 (PCE1). There was no significant difference between the two groups before treatment (P> 0.05). According to the Child classification, serum ALT and AST levels in patients with cirrhosis before treatment were A grade 0.05). Conclusions LiPoPGE1 can reduce the level of ALT.AST in cirrhotic patients with A and B levels. Therefore, LiPoPGE1 could protect liver cells.